Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9265598 | 0.84 | KMT2A (0.45) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8775337 | 0.82 | KMT2A (0.67) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5065834 | 0.82 | KMT2A (0.65) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8775355 | 0.82 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4475179 | 0.78 | CHRM1 (0.59) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL7761926 | 0.76 | CHRM2 (0.53) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8775603 | 0.75 | CHRM1 (0.60) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL8685580 | 0.75 | CHRM1 (0.56) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9187577 | 0.75 | CHRM2 (0.64) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL9431741 | 0.75 | KMT2A (0.56) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585974-B2 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2009-09-08 | — | — | US | disclosed |
| US-20070185137-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| US-7223750-B2 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, the preparation thereof and the application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-29 | — | — | US | disclosed |
| EP-1465893-B1 | DERIVATIVES OF 5-(PYRIDIN-3-YL)-1-AZABICYCLO (3.2.1) OCTANE, THE PREPARATION THEREOF AND THE APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-02-28 | — | — | EP | disclosed |
| US-20050020568-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics | SANOFI (FR) | 2005-01-27 | — | — | US | disclosed |
| EP-0674635-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014803-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185137-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application | PAICS, CYC1, AADAC | CHRM1 32/4885CHRM2 93/4885CHRM4 815/4885 |
| US-20050020568-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics | PAICS, NAT1, TPMT | CHRM1 30/4885CHRM2 79/4885CHRM4 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.